- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PARP inhibitors in the treatment of ovarian cancer ; day:13 ; month:3 ; year:2020 ; pages:1-4
Magazine of European Medical Oncology ; (13.3.2020), 1-4
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-020-00585-1
- URN
-
urn:nbn:de:101:1-2020053100581162327694
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zeimet, Alain G.
- Wieser, Verena
- Knoll, Katharina
- Reimer, Daniel
- Marth, Christian
- SpringerLink (Online service)
Ähnliche Objekte (12)
New treatment option for ovarian cancer: PARP inhibitors
PARP Inhibitors in Ovarian Cancer: A Review
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Characterization of PARP inhibitor resistance in patient-derived ovarian cancer cell lines
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
PARP inhibitors
New treatment option for ovarian cancer: PARP inhibitors
PARP Inhibitors in Ovarian Cancer: A Review
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Characterization of PARP inhibitor resistance in patient-derived ovarian cancer cell lines
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
PARP inhibitors
New treatment option for ovarian cancer: PARP inhibitors
PARP Inhibitors in Ovarian Cancer: A Review
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
Characterization of PARP inhibitor resistance in patient-derived ovarian cancer cell lines
CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer